FDA Removes Authorizations for Three Solvents Used in Food Color Additives

On November 10, 2026, FDA issued two final orders removing (1) the authorized use of methylene chloride as a diluent in color additive mixtures in inks for marking fruit and vegetables and (2) authorizations for methylene chloride, ethylene dichloride, and trichloroethylene as extraction solvents in the production of certain color additives.

The orders partially grant and partially deny petitions submitted by the Environmental Defense Fund (EDF) and other environmental and public health groups and the International Association of Color Manufacturers (IACM). Taken together, however, the orders accomplish all of the actions requested by the EDF petition.

The EDF petition sought removal of the authorizations based on evidence that the solvents induced cancer in laboratory animals. That evidence was sufficient for FDA to remove the use of methylene chloride in ink additives for marking fruit and vegetables. However, FDA determined that the same regulatory mechanism—the Delaney Clause—did not apply to the solvents’ use in the production of certain color additives, because those solvents are only present in those uses as an impurity.

FDA nevertheless removed those authorizations because IACM had separately identified the uses as abandoned in its petition.

The orders are effective January 11, 2027. Comments on the Federal Register notices are due December 12, 2026.

Can FDA revoke a color additive authorization if the additive is found to cause cancer?

Under § 721 of the Federal Food, Drug, and Cosmetic Act (FFDCA), FDA is authorized to regulate color additives used in food, drugs, cosmetics, and certain medical devices. Color additives generally cannot be used unless FDA has approved their use through regulation. The basis for an approval of a color additive is a reasonable certainty of no harm under its intended conditions of use. FDA considers exposure levels, cumulative effects, and relevant safety factors, including those associated with animal studies. Furthermore, new safety evidence may justify repealing an existing authorization if FDA can no longer conclude that the additive meets this standard.

§ 721 established the Delaney Clause, which prohibits approval of certain color additives found to cause cancer in humans or animals. Under §721(d), FDA may revoke a color additive authorization when new safety evidence establishes either FDA can no longer conclude there is reasonable certainty of no harm or the additive must be deemed unsafe under the Delaney Clause.

Does the Delaney Clause apply to carcinogenic impurities in color additives?

FDA found that ethylene dichloride, methylene chloride, and trichloroethylene induce cancer in animals. However, FDA interprets the Delaney Clause to apply to the color additive itself, rather than carcinogenic impurities or nonfunctional constituents. FDA determined that methylene chloride qualifies as a color additive when used as a diluent in inks for marking fruits and vegetables under 21 CFR § 73.1 and therefore revoked that authorization. By contrast, FDA determined that the three solvents are impurities rather than color additives under 21 CFR §§ 73.30, 73.345, and 73.615 and denied the remaining requests.

The affected authorizations concerned the production of annatto extract, paprika oleoresin, and turmeric oleoresin. Unlike the methylene chloride revocation, this action was based on abandonment of the authorized uses rather than the Delaney Clause.

What do FDA’s actions mean for color additive manufacturers?

FDA actions reflect two distinct grounds for removing color additive authorizations: carcinogenicity under the Delaney Clause and abandonment of previously authorized uses. Although EPA has separately restricted methylene chloride and trichloroethylene under the Toxic Substances Control Act (TSCA), EPA cannot regulate FFDCA uses under TSCA. (The Fifth Circuit has since vacated EPA’s TSCA regulation for methylene chloride.)

Manufacturers and suppliers of affected color additives should review their manufacturing processes and formulations to ensure compliance with the amended regulations. Because the extraction solvent uses were reportedly already abandoned, the immediate practical impact of those amendments may be limited. However, the revocation of methylene chloride’s authorization under the Delaney Clause demonstrates that FDA is required to remove an authorized color additive use based on evidence of carcinogenicity, regardless of whether the associated cancer risk is considered minimal.